Selective versus nonselective β-blockade for heart failure therapy: are there lessons to be learned from the COMET trial?
Authors:
- Arthur M. FeldmanAFArthur M. Feldman
- Kirkwood F. AdamsKAKirkwood F. Adams
- Sidney GoldsteinSGSidney Goldstein
- 1 December 2003
- journal article
- review article
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 9 (6) , 444-453
Abstract
No abstract availableKeywords
This publication has 58 references indexed in Scilit:
- Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trialThe Lancet, 2003
- Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart FailureCirculation, 2002
- ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summaryJACC, 2001
- Effect of Carvedilol on Survival in Severe Chronic Heart FailureNew England Journal of Medicine, 2001
- β-Blockers in Congestive Heart Failure: A Bayesian Meta-AnalysisAnnals of Internal Medicine, 2001
- Effects of Controlled-Release Metoprolol on Total Mortality, Hospitalizations, and Well-being in Patients With Heart FailureJAMA, 2000
- HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction—pharmacological approachesJournal of Cardiac Failure, 1999
- Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF)The Lancet, 1999
- The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trialThe Lancet, 1999
- Cardiac adrenergic receptor effects of carvedilolEuropean Heart Journal, 1996